When was ActX founded?

ActX was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Where is ActX located?

ActX is headquartered in Seattle, United States. It is registered at Seattle,Washington.

How many employees does ActX have?

As of Sep 30, 2026, the latest employee count at ActX is 21.

Is ActX a funded company?

ActX is a funded company, having raised a total of $11.8M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 21, 2013.

When was the latest funding round of ActX?

ActX's latest funding was a $***** Series B round on Dec 16, 2022, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.7B in funding in 2026 to date.

Where does ActX rank among its competitors?

ActX ranks 63rd amongst 357 active competitors, of which 121 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was GenSight Biologics, which secured $1.96M in Mar, 2026.

Who are the top competitors of ActX?

ActX's top competitors include MedGenome, Geneoscopy and Intellia Therapeutics. Among them, GenSight Biologics secured the most recent funding round in March, 2026.

ActX - 2026 Company Profile, Funding & Competitors

Company Details

Provider of EHR integrated solutions to healthcare systems. It helps physicians make better decisions about medical treatment, using a patient’s genetic information to guide therapy. Integrated into a physician’s normal software tools (the electronic medical record) and workflow, it analyzes the patient’s genetic information in real time and, for example, alerts the physician if a medication is unlikely to be effective or will cause side effects. It can also warn the physician about serious, actionable medical risks.

Website: www.actx.com/
Social
Registered Address: Seattle,Washington

Key Metrics

Founded Year

2012

Location

Seattle, United States

Stage

Series B

Total Funding

$11.8M in 4 rounds

Latest Funding Round

Series B, Dec 16, 2022, $*****

Investors

Alliance of Angels & 2 more

Ranked

63^rd among 357 active competitors

Employee Count

21 as on Sep 30, 2026

Similar Companies

MedGenome & 505 more

View ActX's full profile

ActX is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Actx, Inc. CIN: 461268976 , United States, Active	Dec 31, 1999	-	10 (As on Dec 31, 2024)	-

ActX has raised a total funding of $11.8M over 4 rounds. Its first funding round was on Nov 21, 2013. ActX has 3 institutional investors.

Here is the list of recent funding rounds of ActX:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 16, 2022	2355828	Series B	7847636	8438376	3389771	9041573
Jul 14, 2017	9708110	Series A	5880722	2389726	6853925	1495047
Jul 17, 2014	1482660	Seed	4259040	3643863	4651405	5757442

Access funding benchmarks and valuations. Sign up today!

View details of ActX's funding rounds and investors

ActX's employee count trend

ActX has 21 employees as of Sep 26. Here is ActX's employee count trend over the years:

Uncover ActX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ActX include MedGenome, Geneoscopy and Intellia Therapeutics. Here is the list of Top 10 competitors of ActX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	70/100
2nd	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	69/100
3rd	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of genome editing therapeutics using CRISPR and Cas9 technology	$85M	Atlas Venture, Novartis & 10 others	68/100
4th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	67/100
5th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	64/100
6th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	63/100
7th	Exosome Diagnostics 2008, Boston (United States), Acquired	Developer of blood-based cancer molecular diagnostics for patient stratification and disease monitoring	$119M	Forbion, NGN Capital & 7 others	62/100
8th	Regulus Therapeutics 2007, San Diego (United States), Acquired	Innovative medicines company reimagining medicine to improve and extend people’s lives	$35M	Ionis Pharmaceuticals, Alnylam & 9 others	62/100
9th	Precipio Diagnostics 1997, New Haven (United States), Public	Provider of cancer diagnostics and second opinion tools	$800K	Enhanced Capital, Connecticut Innovations ... & 3 others	61/100
10th	GenSight Biologics 2011, Paris (France), Public	Developer of viral vector-based gene therapies for retinal neurodegenerative diseases	$76.6M	Perceptive Advisors, Fidelity Investments ... & 17 others	61/100
63rd	ActX 2012, Seattle (United States), Series B	Provider of EHR integrated solutions to healthcare systems	$11.8M	Alliance of Angels, Keiretsu Capital & 1 others	46/100